Low Disease Activity—Irrespective of Serologic Status at Baseline—Associated with Reduction of Corticosteroid Dose and Number of Flares in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Real-Life Observational Study

    February 2018 in “ Seminars in Arthritis and Rheumatism ”
    Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti … Dimitrios T. Boumpas
    Studysummary This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Derivation And Validation Of The Systemic Lupus International Collaborating Clinics Classification Criteria For Systemic Lupus Erythematosus Arthritis & Rheumatism · 2012

    Related research 1

    1. Achievement of Low Disease Activity in Lupus Patients Treated with Belimumab Is Independent of Serologic Status at Baseline: A Real-Life Observational Study 2018